ВЕЛА ЭРНАНДЕС Хосе Мигель (ES),МАРТИН ФОНТЕЛЬЕС Мария Исабель (ES)
申请号：
RU2013156367/04
公开号：
RU2013156367A
申请日:
2012.05.18
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. Sigma ligand for use in the treatment and / or prevention of pain associated with type 2 diabetes. 2. The sigma ligand according to claim 1, wherein the pain associated with type 2 diabetes arises as a result of diabetic neuropathy, diabetic retinopathy, diabetic amyotrophy, gastroparesis, diabetic diarrhea, neuropathic arthropathy, bladder neuropathy, diabetic nephropathy and / or diabetic foot syndrome. 3. The sigma ligand according to any one of claims 1 and 2, which is selected from a sigma receptor antagonist, preferably selected from a neutral antagonist, an inverse agonist and a partial antagonist. The sigma ligand according to any one of claims 1 and 2, having the general formula (I) wherein R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR, —C (O) OR, —C (O) NRR, —CH = NR, —CN, —OR, —OC ( O) R, -S (O) -R, -NRR, -NRC (O) R, -NO, -N = CRR and halogen； R bran from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl -C (O) OR, -C (O) NRR, -CH = NR, -CN, -OR, -OC (O) R, -S (O) -R, -NRR, -NRC (O) R, -NO, -N = CRR and halogen； R and R are independently selected from the group consisting of hydrogen�1. Сигма-лиганд для применения в лечении и/или предотвращении боли, связанной с диабетом 2 типа.2. Сигма-лиганд по п.1, где боль, связанная с диабетом 2 типа, возникает в результате диабетической невропатии, диабетической ретинопатии, ди
